Fat Acceptance Was Great Until the Rich Found a Pill

The Timeline Nobody Wants to Acknowledge

The body positivity movement, in its original form, was a radical project. It emerged from fat activism in the 1960s, rooted in disability rights and anti-racist politics. Its demand was structural: stop discriminating against people based on body size. In healthcare, in hiring, in housing. It was not, originally, about learning to love your reflection.

Then the mainstream discovered it. By the mid-2010s, body positivity had become a brand asset. Dove ran campaigns featuring diverse body types. Plus-size influencers built empires. Meghan Trainor sang that she was “all about that bass,” rejecting “stick-figure silicone Barbie doll” aesthetics. Lizzo became a cultural icon partly by being visibly, defiantly large. The message felt like a settled consensus: all bodies are good bodies.

Then semaglutideA GLP-1 receptor agonist used to treat type 2 diabetes and obesity. Sold as Ozempic and Wegovy, it suppresses appetite by mimicking gut hormones. entered the chat. Ozempic, originally a diabetes medication, turned out to suppress appetite so effectively that Hollywood adopted it as the worst-kept secret since cosmetic surgery. By 2024, Novo Nordisk’s semaglutide products (Ozempic, Wegovy, Rybelsus) were generating billions annually. Comedian Nikki Glaser opened the 2025 Golden Globes with “Good evening, and welcome to the 82nd Golden Globes, Ozempic’s biggest night.” Nobody pretended she was wrong.

The Contradiction That Walks the Red Carpet

The same celebrities who built careers on body acceptance began shrinking. Meghan Trainor, who once rejected “stick-figure” aesthetics, appeared at the 2025 Billboard Women in Music event dramatically thinner after using Mounjaro. Most of the social media comments were about her body, not her music. She told the press she was “trying to learn at 31 how to not give strangers power,” which is a reasonable response from a human being and completely misses the structural point.

Sharon Osbourne became the cautionary tale nobody wanted. She started Ozempic in late 2022, lost 42 pounds, dropped under 100 pounds, and found she couldn’t stop losing. “I’m too gaunt,” she told the Daily Mail. “Be careful what you wish for.” Her warning about keeping the drug from teenagers (“they will go berserk on it”) went largely ignored by an industry busy discovering that the drugs work on adults too.

Plus-size influencers faced impossible choices. When influencer Rosey Beeme (187,000 followers) used Mounjaro, she described the community response as “unhealthy and dare I say culty.” Kiki Monique publicly shared medical records proving her pre-diabetes diagnosis, because apparently women must now produce clinical documentation to justify decisions about their own bodies. Another influencer, Ella Halikas, ultimately declined the medication out of fear it would “betray” her community.

Ozempic, Body Positivity, and the Class Fracture

Here is where the comfortable consensus cracks. Semaglutide costs upward of $1,000 per month without insurance in the United States. State Medicaid spending on GLP-1 drugs jumped from $577 million in 2019 to $3.9 billion in 2023, nearly a sevenfold increase, and coverage remains patchy. As psychologist Nafees Alam wrote in Psychology Today, body positivity has become “a consolation prize” for those who can’t afford the alternative.

This is not a new dynamic. The ability to conform to beauty standards has always been correlated with wealth. But the pharmaceutical industrialization of thinness makes the class dimension blunter than ever. When the path to the “acceptable” body runs through a prescription that costs more than many people’s monthly grocery budget, telling those people to love themselves as they are starts to sound less like empowerment and more like managed expectations. As the Irish Times put it, the widening gap between thin-and-rich and overweight-and-poor threatens to deepen divides across both class and race.

If you’re interested in the mechanics of why drugs cost what they do in the United States, we’ve written about the pharmaceutical pricing system before. The short version: it’s not an accident.

We Have Been Here Before

The 1990s had heroin chicA 1990s fashion aesthetic glamorizing extreme thinness, pallor, and gauntness, visually associated with drug use culture. Criticized for normalizing unhealthy body ideals.: gaunt models, pale skin, hollowed eyes, Kate Moss on the cover of everything. It was an aesthetic that glamorized illness, and it took years and a public health crisis to push back against it. The parallels to the current moment are close enough to be alarming. The 2026 Oscars red carpet, with its parade of dramatically sharpened jawlines and visible rib cages, prompted the comparison from multiple outlets: Ozempic chic is heroin chic with a prescription and better PR.

The critical difference is the mechanism. Heroin chic was, at least in theory, about an aesthetic rather than a specific product. Ozempic chic is backed by a pharmaceutical company that spent $491 million on advertising in the first half of 2023 alone. The beauty standard isn’t just emerging from culture; it’s being manufactured and marketed.

The SteelmanA rhetorical technique where you present the strongest possible version of an opponent's argument before refuting it. The opposite of a straw man., and Why It Only Goes So Far

People have the right to make decisions about their own bodies. Full stop. GLP-1 drugs are legitimate medications that help millions of people with diabetes and obesity. Obesity medicine specialist Dr. Chika Anekwe makes the fair point that “people don’t usually call insulin or cholesterol-lowering drugs ‘cheating.'” The stigma around weight-loss medication reflects the deeper problem that obesity still isn’t fully accepted as a medical condition.

This argument is correct, and it’s also incomplete. The individual right to use medication is not what’s at stake. What’s at stake is a culture that spent a decade telling people their bodies were fine, then, the moment a pharmaceutical shortcut to thinness became available, collectively sprinted in the opposite direction. The problem isn’t that individuals are taking Ozempic. The problem is that an entire cultural movement evaporated the instant thinness became purchasable again.

What Body Positivity Was, and What It Became

Writer Catherine Mhloyi, in TIME, traced how the body positivity movement was defanged long before Ozempic arrived. The movement began with Black women activists in the 1960s addressing fatphobia’s connection to anti-Black racism. But “fat acceptance groups that followed also chose to center whiteness,” and the shift from liberation to personal “self-love” extracted the political edge. By the time Instagram influencers were monetizing body acceptance, the movement had become, in Mhloyi’s words, “a house of cards.”

Ozempic didn’t kill body positivity. It revealed that mainstream body positivity was already hollow. As beauty reporter Jessica DeFino observed at a Stanford panel, the wellness industry had already rebranded weight loss as self-care during the 2010s. Ozempic simply made the quiet part loud: for many of its most visible proponents, body acceptance was a position of necessity, not conviction. Once the necessity changed, so did the position.

The original fat liberationA political movement originating in the 1960s demanding structural change to end discrimination based on body size, rooted in disability rights and anti-racist activism. movement, the one that demanded structural change rather than personal affirmation, was always more honest about this. Virgie Tovar, an author and weight-based discrimination expert, argues that body size should be “a morally neutral feature of human diversity.” That framing doesn’t collapse when someone takes a pill. The version of body positivity that does collapse is the one that was always more about marketing than politics.

Where This Leaves Us

The 2026 Oscars red carpet was not, in itself, the problem. Celebrities have always been thinner, more sculpted, and more surgically enhanced than the general population. What made this particular red carpet land differently is that it arrived at the end of a decade that was supposed to have moved past all of that. The body positivity era promised a cultural shift. What it delivered was a holding pattern.

Family physician Mara Gordon, writing for NPR, put it plainly: GLP-1 drugs “don’t undo the harms of diet culture, distorted body image and pervasive weight stigma.” The real question was never whether Ozempic works. It was whether we meant any of it when we said that bodies of all sizes deserve dignity. The red carpet suggests an answer, and it’s not the one anyone was hoping for.

The Timeline Nobody Wants to Acknowledge

The body positivity movement, in its radical original form, was a political project. It emerged from fat activism in the 1960s, rooted in disability rights, anti-racist politics, and demands for structural change: stop discriminating against people based on body size in healthcare, hiring, housing, and public life. It was not, originally, about learning to love your reflection. It was about dismantling systems that punished people for their bodies.

Then the mainstream discovered it. By the mid-2010s, body positivity had been thoroughly co-opted as a brand asset. Dove ran campaigns featuring diverse body types. Plus-size influencers built empires on platforms that monetized their visibility. Meghan Trainor sang that she was “all about that bass,” rejecting “stick-figure silicone Barbie doll” aesthetics. Lizzo became a cultural icon partly by being visibly, defiantly large. The message appeared to be a settled cultural consensus: all bodies are good bodies. The movement had won, or at least it looked that way from the outside.

Then semaglutideA GLP-1 receptor agonist used to treat type 2 diabetes and obesity. Sold as Ozempic and Wegovy, it suppresses appetite by mimicking gut hormones. entered the picture. Ozempic, a GLP-1 receptor agonistA class of drugs that activate glucagon-like peptide-1 receptors to reduce appetite and lower blood sugar. Used to treat type 2 diabetes and obesity. originally developed by Novo Nordisk for type 2 diabetes management, turned out to suppress appetite so effectively through its action on the brain’s satiety signals that Hollywood adopted it as the worst-kept secret since cosmetic surgery. By 2024, Novo Nordisk’s semaglutide franchise (Ozempic, Wegovy, and Rybelsus) was generating billions in annual revenue. Comedian Nikki Glaser opened the 2025 Golden Globes with “Good evening, and welcome to the 82nd Golden Globes, Ozempic’s biggest night.” Nobody pretended she was wrong.

The Contradiction That Walks the Red Carpet

The same celebrities who built careers, brands, and cultural cachet on body acceptance began shrinking visibly. Meghan Trainor, who once rejected “stick-figure” aesthetics in the song that launched her career, appeared at the 2025 Billboard Women in Music event dramatically thinner. She lost significant weight with the help of Mounjaro (tirzepatide, a dual GIP/GLP-1 agonist). When she was honored at the event, most of the social media comments were about her body, not her music. She told the press she was “trying to learn at 31 how to not give strangers power,” which is a reasonable response from a human being dealing with public scrutiny and completely misses the structural point her own career helped establish.

Sharon Osbourne became the cautionary tale. She started Ozempic in December 2022, lost 42 pounds in under a year, and dropped below 100 pounds when her target was 105. She couldn’t reverse course. “I’m too gaunt and I can’t put any weight on,” she told the Daily Mail. “Be careful what you wish for.” Her specific warning about teenagers (“Don’t give it to teenagers, it’s just too easy. You can lose so much weight and it’s easy to become addicted to that”) went largely unheeded by an industry and culture busy discovering that the drugs worked on wealthy adults who didn’t have diabetes, too.

The influencer ecosystem fractured along predictable lines. When plus-size influencer Rosey Beeme (187,000 followers) used Mounjaro, she described the community response as “unhealthy and dare I say culty.” Kiki Monique (137,000 followers) publicly shared her medical records showing a pre-diabetes diagnosis, because apparently women must now produce clinical documentation to justify decisions about their own bodies. Ella Halikas (267,000 followers) ultimately declined the medication entirely, fearing it would “betray” her community. As NBC News reported, the tension revealed a “fundamental disconnect” within the movement between individual health autonomy and collective identity.

The Class Fracture: Ozempic for the Rich, Self-Love for Everyone Else

Here is where the comfortable consensus cracks along economic lines. Semaglutide costs upward of $1,000 per month without insurance in the United States; Newsweek reported the range as $1,000 to $1,400. State Medicaid spending on GLP-1 drugs surged from $577.3 million in 2019 to $3.9 billion in 2023, a nearly sevenfold increase, yet coverage remains inconsistent. Dr. Cynthia Cox of the Kaiser Family Foundation told Newsweek that “one thousand dollars a month per person is a massive outlay.” Dr. Robert Klitzman warned that “if two-thirds of Americans needed them, it would bankrupt the health care system.”

Psychologist Nafees Alam, writing in Psychology Today in February 2025, crystallized the dynamic in his title: “Ozempic for the Rich, Body Positivity for the Poor.” His argument is that body positivity has become “a consolation prize” for those who can’t afford pharmaceutical interventions. Weight loss is medicalized for the wealthy while lower-income populations are told to embrace their natural bodies, a dynamic that compounds existing barriers: limited healthcare access, food insecurity, and unsafe exercise environments. The structural inequality isn’t a bug in the body positivity narrative; it’s the feature that Ozempic made impossible to ignore.

If you’re interested in the mechanics of why drugs cost what they do in the United States, with its layers of pharmacy benefit managersA company that administers prescription drug benefits on behalf of insurers and employers, negotiating rebates with manufacturers and deciding which drugs are covered., gross-to-net bubblesThe growing gap between a drug's list price and the net revenue manufacturers actually receive after rebates and discounts; patients often pay based on the inflated list price., and deliberate opacity, we’ve written about the pharmaceutical pricing system before. The short version: the price is not an accident and the complexity is the point.

The Heroin ChicA 1990s fashion aesthetic glamorizing extreme thinness, pallor, and gauntness, visually associated with drug use culture. Criticized for normalizing unhealthy body ideals. Parallel: We Have Been Here Before

The 1990s had heroin chic: gaunt models, pale skin, hollowed eyes, Kate Moss on the cover of everything. It was an aesthetic that glamorized illness, and it took years, public outcry, and a shift in cultural politics to push back against it. The parallels to the current moment are close enough to be alarming. The 2026 Oscars red carpet, with its parade of dramatically sharpened jawlines, pronounced collarbones, and visibly fragile silhouettes, prompted the comparison from multiple outlets. Observers noted what looked like a competition in who could appear most ethereal.

The critical difference is the mechanism. Heroin chic was, at least in theory, about an aesthetic rather than a specific commercial product. Ozempic chic is backed by a pharmaceutical corporation that spent $491 million on advertising in the first half of 2023 alone, as NPR reported. The beauty standard isn’t just emerging organically from culture; it’s being manufactured, marketed, and sold on a subscription basis. The Irish Times reported that pandemic-era hospitalizations for anorexia and bulimia had already spiked before GLP-1 drugs became a cultural phenomenon.

The SteelmanA rhetorical technique where you present the strongest possible version of an opponent's argument before refuting it. The opposite of a straw man., and Why It Only Goes So Far

People have the right to make decisions about their own bodies. Full stop. GLP-1 receptor agonists are legitimate, FDA-approved medications that help millions of people manage type 2 diabetes and clinically significant obesity. Obesity medicine specialist Dr. Chika Anekwe makes the entirely fair point that “people don’t usually call insulin or cholesterol-lowering drugs ‘cheating.'” The persistent stigma around weight-loss medication reflects the deeper problem that obesity still isn’t fully accepted as a medical condition requiring treatment rather than a moral failing requiring willpower.

Influencer Kiki Monique insisted: “I’m doing this so people understand these drugs aren’t just because people want to get skinny.” She’s right. Many users have genuine medical indications. Polycystic ovarian syndrome, pre-diabetes, cardiovascular risk reduction: these are real reasons to take real medication.

This argument is correct, and it’s also incomplete. The individual right to use medication is not what’s at stake in the cultural conversation. What’s at stake is a culture that spent a decade telling people their bodies were fine, building entire media ecosystems around that message, then, the moment a pharmaceutical shortcut to thinness became available, collectively sprinted in the opposite direction. The problem isn’t that individuals are taking Ozempic. The problem is that an entire cultural movement evaporated the instant thinness became purchasable again for those with the means to buy it.

What Body Positivity Was, and What It Became

Writer Catherine Mhloyi, in TIME, traced how the body positivity movement was defanged long before Ozempic arrived. The movement began with Black women activists in the 1960s addressing fatphobia’s connection to anti-Black racism. But “fat acceptance groups that followed also chose to center whiteness,” and the shift from liberation to personal “self-love” extracted the political edge. “Anything can be done in the name of self-love,” Mhloyi wrote, pointing out that without community-based resistance, individuals were “easily divided and conquered.” By the time Instagram influencers were monetizing body acceptance through brand deals and sponsored content, the movement had become, in Mhloyi’s words, “a house of cards.”

Ozempic didn’t kill body positivity. It revealed that mainstream body positivity was already hollowed out. As beauty reporter Jessica DeFino observed at a 2025 Stanford Clayman Institute panel, the wellness industry had rebranded weight loss as self-care during the 2010s, then pivoted to “above the chin” products like skincare when body positivity gained mainstream traction. DeFino noted that both Ozempic and Botox “use systems of discrimination to justify their existence”: fatphobia for weight-loss drugs, ageism for anti-aging treatments. The mechanism is the same: position appearance modification as rational protection against real discrimination, which makes refusal look irrational.

The original fat liberationA political movement originating in the 1960s demanding structural change to end discrimination based on body size, rooted in disability rights and anti-racist activism. movement, the one that demanded structural change rather than personal affirmation, was always more honest about this vulnerability. Virgie Tovar argues that body size should be regarded as “a morally neutral feature of human diversity,” and that individuals shouldn’t face pressure to alter their appearance to obtain healthcare or employment. That framing doesn’t collapse when someone takes a pill. The version of body positivity that collapses is the version that was always more about marketing than politics, more about feeling than organizing.

Where This Leaves Us

The 2026 Oscars red carpet was not, in itself, the problem. Celebrities have always been thinner, more sculpted, and more surgically enhanced than the general population. That’s not new, and pretending otherwise is its own kind of dishonesty. What made this particular red carpet land differently is that it arrived at the end of a decade that was supposed to have moved past all of that. The body positivity era promised a fundamental cultural shift in how we valued human bodies. What it delivered was a holding pattern: conditional acceptance that lasted exactly as long as there was no pharmacological alternative.

Family physician Mara Gordon, writing for NPR, noted that GLP-1 drugs “don’t undo the harms of diet culture, distorted body image and pervasive weight stigma.” Novo Nordisk’s advertising budget won’t fund eating disorder treatment. The red carpet won’t come with a disclaimer about the $1,000 monthly cost of looking like that. And the influencers who built followings on self-acceptance won’t all explain why that message was apparently negotiable.

The real question was never whether Ozempic works. Of course it works. The real question was whether we meant any of it when we said that bodies of all sizes deserve dignity, respect, and equal treatment. The 2026 Oscars red carpet, with its gallery of increasingly skeletal glamour, suggests an answer. It is not the one the body positivity movement was hoping for, and it is not one the rest of us should be comfortable with either.